17:10 IST
NSE
Earnings Call
SMS Pharmaceuticals Investor Presentation: Key Takeaways
SMS Pharma reported Q1FY27 revenue of ₹207 Cr (+6% YoY) with stable EBITDA margins at ~20%. Strategy focuses on high-value APIs and peptide R&D.